1-3 of 3
Estil A. Vance, MD
Close
Save search
Sort by
Journal Articles

Differential Gene Expression Analysis Predicts For Response To Bortezomib In The Treatment Of Steroid Refractory Chronic Graft-Versus-Host Disease (cGVHD)

Free
Alan M Miller, MD, PhD, Reva Schneider, MD, Estil A. Vance, MD, Edward Agura, MD, Sheila Powell, RN, Virginia Pascual, MD, Indira Munagala, Huanying Qin, MS
Journal: Blood
Blood (2013) 122 (21): 4587.
https://doi.org/10.1182/blood.V122.21.4587.4587
Published: 2013
Journal Articles

Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan (CLO/BU) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies

Free
Edward Agura, MD, R. Brian Berryman, MD, Luis Pineiro, MD, Mirjana Tadic-Ovcina, Ryan Woelfel, Estil A. Vance, MD, Joseph W. Fay, MD
Journal: Blood
Blood (2008) 112 (11): 4320.
https://doi.org/10.1182/blood.V112.11.4320.4320
Published: 2008
Journal Articles

Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies and Diseases.

Free
Edward D. Agura, MD, R. Brian Berryman, MD, Joseph W. Fay, MD, FACP, Luis A. Pineiro, MD, Estil A. Vance, MD, Mirjana Tadic-Ovcina
Journal: Blood
Blood (2007) 110 (11): 4954.
https://doi.org/10.1182/blood.V110.11.4954.4954
Published: 2007